Condition
RAF Mutation
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
80.0%
4 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 1 (4)
P 2 (1)
Trial Status
Terminated4
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06287463Phase 1Terminated
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
NCT06299839Phase 1Recruiting
PAS-004 in Patients With Advanced Solid Tumors
NCT04985604Phase 2Terminated
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
NCT07121829Phase 1Terminated
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NCT05831995Phase 1Terminated
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Showing all 5 trials